Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to $3.5 million.

  • Intellia Therapeutics' Change in Account Payables rose 16230.19% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $464000.0, marking a year-over-year decrease of 9501.34%. This contributed to the annual value of $6.8 million for FY2024, which is 16962.73% up from last year.
  • According to the latest figures from Q3 2025, Intellia Therapeutics' Change in Account Payables is $3.5 million, which was up 16230.19% from -$2.6 million recorded in Q2 2025.
  • Intellia Therapeutics' 5-year Change in Account Payables high stood at $5.6 million for Q1 2024, and its period low was -$7.7 million during Q3 2023.
  • Its 5-year average for Change in Account Payables is $226052.6, with a median of $736000.0 in 2021.
  • Over the last 5 years, Intellia Therapeutics' Change in Account Payables had its largest YoY gain of 215263.16% in 2023, and its largest YoY loss of 37450.74% in 2023.
  • Quarter analysis of 5 years shows Intellia Therapeutics' Change in Account Payables stood at $2.4 million in 2021, then crashed by 68.74% to $750000.0 in 2022, then soared by 425.47% to $3.9 million in 2023, then crashed by 63.56% to $1.4 million in 2024, then surged by 140.88% to $3.5 million in 2025.
  • Its Change in Account Payables stands at $3.5 million for Q3 2025, versus -$2.6 million for Q2 2025 and -$1.9 million for Q1 2025.